Research programme: IgE synthesis inhibitors - Pfizer
Alternative Names: Research programme: IgE secretion inhibitors - Pfizer; Research programme: interleukin-4 pathway inhibitors - PfizerLatest Information Update: 13 Mar 2008
At a glance
- Originator Pfizer
- Class Small molecules
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Allergic asthma; Hypersensitivity
Most Recent Events
- 06 Sep 2004 Data presented at the 18th International Symposium of Medicinal Chemistry (ISMC-2004) have been added to the adverse events and Obstructive Airways Disease pharmacodynamics sections
- 07 Oct 2003 The drug targets accepted by Pfizer have entered the compound screening phase at Pfizer
- 26 Jun 2002 Rigel Pharmaceuticals has concluded its research collaboration with Pfizer